# A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

> **NCT07559396** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 16 (estimated)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** INCB123667

## Key facts

- **NCT ID:** NCT07559396
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2027-01-04
- **Final completion:** 2027-01-04
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559396, "A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07559396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*